Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer

NCT07315113 is registered in ClinicalTrials.gov with Nuvectis Pharma, Inc. as lead sponsor.

NCT NCT07315113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07315113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer
Lead sponsor
Nuvectis Pharma, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 18, 2025
Completion date
June 30, 2027
Enrollment
18 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutated non-small cell lung cancer patients, egfr mutation positive non-small cell lung cancer